ライフサイエンスコーパス: vomiting

1 nd/or the gastrointestinal tract (persistent vomiting).

2 ing, eye bulging, bradycardia, cyanosis, and vomiting.

3 ad nausea and 15 (17%) versus three (5%) had vomiting.

4 spitalization, and frequency of diarrhea and vomiting.

5 complaints of epigastric abdominal pain and vomiting.

6 , headache, nausea, diarrhea, dizziness, and vomiting.

7 culitis accompanying with abdominal pain and vomiting.

8 of vision in her right eye, ocular pain and vomiting.

9 , but increases the occurrence of nausea and vomiting.

10 ED visits for gastroenteritis, diarrhea, and vomiting.

11 o an adverse event, oxygen desaturation, and vomiting.

12 e than glargine, were nausea, diarrhoea, and vomiting.

13 per abdominal pain radiating to the back and vomiting.

14 verse events (AEs) were fatigue, nausea, and vomiting.

15 ctory and somatosensory stimuli, nausea, and vomiting.

16 a 2-day history of abdominal distention and vomiting.

17 esented with a history of abdominal pain and vomiting.

18 low risk of chemotherapy-induced nausea and vomiting.

19 ss of consciousness, headache, and/or nausea/vomiting.

20 adverse events such as nausea, diarrhea, and vomiting.

21 eduction in PTH) and self-reported nausea or vomiting.

22 s and specific symptoms of pain, nausea, and vomiting.

23 acial dysmorphisms, and periods of fever and vomiting.

24 by risk for chemotherapy-induced nausea and vomiting.

25 nted acutely with severe epigastric pain and vomiting.

26 om Index) for nausea (1.8 vs 1.0; P = .005), vomiting (1.6 vs 0.5; P = .001), and overall symptoms (1

27 and promethazine after 24 hours (episodes of vomiting, 1 [IQR, 0-5] for metoclopramide vs 2 [IQR, 0-3

28 ausea (12.4% and 9.1% vs 5.1% and 7.3%), and vomiting (10.4% and 7.5% vs 7.1% and 3.1%).

29 [3.7%] vs. 74 patients [6.2%]; P=0.006) and vomiting (100 patients [8.4%] vs. 194 patients [16.2%];

30 e nausea (16%), prolonged QT interval (12%), vomiting (11%), and dysgeusia (11%); most were </= grade

31 tigue (18 [56%] of 32 vs two [40%] of five), vomiting (12 [38%] of 32 vs zero), and anaemia (eight [2

32 [85%] of 189 patients), nausea (130 [69%]), vomiting (125 [66%]), and an increase in alanine aminotr

33 s included nausea (eight [7%] vs one [<1%]), vomiting (13 [11%] vs one [<1%]), musculoskeletal pain (

34 eutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).

35 6 [15%] of 233 patients vs five [2%] of 223; vomiting: 15 [6%] vs six [3%]; diarrhoea: 32 [14%] vs 15

36 rthralgia (4 [5%] vs 1 [1%]), and nausea and vomiting (2 [2%] vs 3 [4%]).

37 nia (24 [24%]), constipation (23 [23%]), and vomiting (20 [20%]), and were predominantly grade 1 or 2

38 [54% vs 23%; P < .001] and grade 3/4 nausea/vomiting [20% vs 11%; P = .03]), while rates of grade 3

39 [12%]), dyspepsia (24 [8%] vs 18 [6%]), and vomiting (21 [7%] vs 25 [8%]), with similar rates of stu

40 nts in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group (3.9%; P = .0

41 inal symptoms (nausea [47%], diarrhea [36%], vomiting [21%]).

42 were neutropenia (30 [27%] of 113 patients), vomiting (22 [19%]), and leucopenia (17 [15%]).

43 th neutropenia (30 [26.5%] of 113 patients), vomiting (22 [19.5%]), and leucopenia (17 [15.0%]) in th

44 erythrodysaesthesia syndrome (87 [18%]), and vomiting (24 [5%]).

45 CF versus LRD results were as follows: POD2 vomiting (28% vs 14%; P = 0.09), and significant increas

46 vs 23 [35%]), nausea (47 [73%] vs 34 [52%]), vomiting (29 [45%] vs 12 [18%]), and diarrhoea (22 [34%]

47 upper gastrointestinal hemorrhage (3%), and vomiting (3%).

48 Rash (84 reports), itching (46 reports), and vomiting (30 reports) were the 3 most frequently occurri

49 xygen desaturation (353 patients [5.6%]) and vomiting (328 [5.2%]) were the most common of these adve

50 joint pains, 37 (5%) had nausea, 36 (4%) had vomiting, 34 (4%) had neuropathy, 23 (3%) had transamini

51 rhea (38%), nausea (38%), fatigue (37%), and vomiting (35%).

52 el-prednisone, including nausea (42% v 26%), vomiting (36% v 17%), fatigue (29% v 23%), and increased

53 hea [86%/83%/74%], nausea [46%/48%/48%], and vomiting [37%/38%/43%]).

54 [5%] vs 23 [corrected] [3%]), and nausea or vomiting (38 [5%] vs 41 [6%]).

55 ea (56 [10%] of 556 vs 64 [11%] of 585), and vomiting (39 [7%] of 556 vs 23 [4%] of 585).

56 nausea (75%), fatigue (70%), anorexia (64%), vomiting (43%), weight loss (32%), and diarrhea (32%), w

57 group), diarrhoea (59 [13%] vs 28 [6%]), and vomiting 48 [11%] vs 17 [4%]), which occurred less frequ

58 thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events.

59 gue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which were generally grade 1 or 2.

60 luded fever (91%), abdominal pain (84%), and vomiting (49%).

61 6% [49 of 57]), ataxia (54% [29 of 54]), and vomiting (54% [29 of 54]) were common initial clinical m

62 up and nausea (in 97 [55%] of 175 patients), vomiting (63 [36%]), and anaemia (62 [35%]) in the chemo

63 not affect time to resolution of nausea and vomiting (64.5 vs 74.3 hours; P = 0.404) or consumption

64 and 8 [31%] patients in DRMPa200Z group) and vomiting (7 [12%] patients in MPa100Z group, 7 [11%] pat

65 7.0%), headache (77.9%), joint pain (73.7%), vomiting (71.2%), and diarrhea (70.6%).

66 30.7% [95% CI, 26.8%-34.7%]; P = .01) and no vomiting (87.1% [95% CI, 83.8%-90.0%) vs 78.0% [95% CI,

67 1.6% [95% CI, 37.4%-45.3%]; P < .001) and no vomiting (91.8% [95% CI, 89.0%-94.0%] vs 82.2% [95% CI,

68 sick with typical NoV infection symptoms of vomiting (93.4%), abdominal pain (90.4%), nausea (60.0%)

69 glucose levels in motion-induced nausea and vomiting, a finding that may provide insight into other

70 associated with reduced odds of posttussive vomiting, a marker of more clinically significant illnes

71 ose, he presented with headache, nausea, and vomiting; a brain magnetic resonance imaging scan showed

72 ts or who experience breakthrough nausea and vomiting; a recommendation to administer dexamethasone o

73 Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed b

74 ge to the ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure,

75 number of symptoms and higher frequencies of vomiting, abdominal pain, swollen stomach, and loss of a

76 For radiation-induced nausea and vomiting, adjustments were made to anatomic regions, ris

77 Importance: Nausea and vomiting affects approximately 85% of pregnant women.

78 In each treatment group, the risk of vomiting after administration of any dose of the study a

79 tient began to experience abdominal pain and vomiting after ingestion of egg approximately one day af

80 children treated with ondansetron continued vomiting after the administration of the therapy vs 93%

81 ol group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ administration).

82 findings (>60 years, intoxication, headache, vomiting, amnesia, seizure, or trauma above the clavicle

83 Recent vomiting and abdominal discomfort were due to a high-gra

84 tolerated; the most common side effects were vomiting and abdominal pain.

85 prokinetic effects and significantly reduced vomiting and also improved other symptoms of diabetic ga

86 Vomiting and bloody stool were frequently observed in bo

87 Vomiting and cough were prevalent symptoms in the first

88 t requiring surgery [grade 3]; recurrence of vomiting and dehydration [grade 3]; diarrhoea and fever

89 s each year as a result of severe diarrhoea, vomiting and dehydration due to the actions of cholera t

90 s and other animals that is characterized by vomiting and diarrhea and caused by a variety of pathoge

91 The final patient developed vomiting and diarrhea, started palliative care, and died

92 ted in Ireland caused illness manifesting by vomiting and diarrhoea.

93 Incidences of vomiting and drug-hypersensitivity reactions were signif

94 ea and G4 thrombocytopenia at 350 mg; and G3 vomiting and G3 diarrhea at 500 mg.

95 mptomatic in 2 patients and symptomatic with vomiting and headache in 2 patients.

96 He was vomiting and in distress, and he had a history of thalas

97 izophrenia-like behaviours, anxiety, memory, vomiting and pain.

98 with evidence of dehydration associated with vomiting and severe diarrhea.

99 s); adverse events were primarily nausea and vomiting and sleep disorders.

100 s ribavirin due to serious adverse events of vomiting and tachycardia.

101 ECS is involved in the control of nausea and vomiting and visceral sensation.

102 53-year-old woman presented with nausea and vomiting and was noted to have an asymptomatic elevated

103 ; P = .068), and mild or greater severity of vomiting and/or diarrhea (20.0% vs. 37.5%; P = .074) wer

104 ovirus VLP vaccine reduced norovirus-related vomiting and/or diarrhea; field efficacy studies are pla

105 with acute gastroenteritis (diarrhea and/or vomiting) and 818 healthy controls frequency matched by

106 us, pain, presyncope, urinary retention, and vomiting) and one patient had a grade 4 adverse event (l

107 nal-reported morbidity (fever, diarrhea, and vomiting) and serious infectious events (SIEs) (gastroen

108 (15%) dysgeusia, 18 (28%) versus five (15%) vomiting, and 12 (19%) versus two (6%) neutropenia.

109 ase characterized by fever, severe diarrhea, vomiting, and a high fatality rate in Guinea.

110 presents itself in association with nausea, vomiting, and abnormal sensitivity to light, noise, and

111 eumonia, ileus, and postoperative nausea and vomiting, and also improved recovery of bowel function,

112 reaction including erythema, abdominal pain, vomiting, and anaphylactic shock.

113 than men, functional chest pain, dyspepsia, vomiting, and anorectal pain do not appear to vary by ge

114 despite severe side effects such as nausea, vomiting, and anorexia that compromise quality of life a

115 Nausea, vomiting, and asymptomatic hyperCKemia should be recogni

116 o group were arthralgia, diarrhea, pruritus, vomiting, and chest pain.

117 old man had acute onset of headache, nausea, vomiting, and confusion.

118 ose-limiting toxicities were grade 3 nausea, vomiting, and diarrhea in 2 patients, and grade 3 skin r

119 Nausea, vomiting, and diarrhea were more common in the apremilas

120 equent adverse events were low-grade nausea, vomiting, and diarrhea.

121 nificantly associated with death were fever, vomiting, and diarrhoea.

122 e world during childhood and cause diarrhea, vomiting, and fever.

123 e world during childhood and cause diarrhea, vomiting, and fever.

124 0(th) %ile of normal, 85.75 minutes), recent vomiting, and gastroparesis cardinal symptom index-daily

125 r (D2R) antagonist approved to treat nausea, vomiting, and headache in humans has potent in vitro and

126 e the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium

127 enia (n=4), diarrhoea (n=2), melena, stroke, vomiting, and intestinal infarction; all but one patient

128 ropenia, oesophagitis, diarrhoea, nausea and vomiting, and mucositis were significantly worse in pati

129 common (31 participants with nausea, 31 with vomiting, and one with diarrhoea), then oral pruritus af

130 that early solid intake may increase nausea, vomiting, and overall complications.

131 ique on postoperative opioid use, nausea and vomiting, and pain scores.

132 stroesophageal reflux disease [GERD], nausea/vomiting, and pain) align with clinical symptomology and

133 iated with savolitinib were nausea, fatigue, vomiting, and peripheral edema.

134 physiological changes resulting in diarrhea, vomiting, and proinflammatory diseases, making both the

135 oral rehydration salt solution, severity of vomiting, and serum levels of rotavirus-specific IgA.

136 female, professional diver, reported nausea, vomiting, and systemic hives 20 to 30 minutes after inge

137 mon clinical features include fever, nausea, vomiting, and tinnitus.

138 al with acute abdominal pain, diarrhoea, and vomiting, and was admitted to the hospital because of de

139 epigastric pain, postprandial pain, nausea, vomiting, and weight loss.

140 participants, included nausea, diarrhea, and vomiting, and were mild in severity.

141 d adverse events (grade 1 or 2) were nausea, vomiting, anorexia, and fatigue, which were well managed

142 hat devastate quality of life (e.g., nausea, vomiting, anorexia, weight loss).

143 In Rome IV functional nausea and functional vomiting are now described.

144 educed the half-time of gastric emptying and vomiting, as well as nausea, abdominal pain, bloating, a

145 oup had CPAP-related adverse events, such as vomiting, aspiration, and nasal, skin, or eye trauma.

146 inol and nabilone), which include nausea and vomiting associated with chemotherapy and appetite stimu

147 is (MS) patients and to alleviate nausea and vomiting associated with chemotherapy in cancer patients

148 etic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic

149 ot syndrome (2% v 20%); mucositis (6% v 5%); vomiting (both, 5%); and myalgia (4.5% v 1%).

150 ed trial of patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s

151 symptoms in patients with chronic nausea and vomiting caused by gastroparesis or gastroparesis-like s

152 n to prevent chemotherapy-induced nausea and vomiting (CINV) for patients undergoing high-dose chemot

153 the risk of chemotherapy-induced nausea and vomiting (CINV), these factors are rarely considered whe

154 , ranging from 0.10 for anorexia to 0.54 for vomiting (Cohen kappa statistic).

155 d gastric emptying and significantly reduced vomiting, compared with placebo.

156 definitions of grade of severity for nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, f

157 sicians of six toxicities (anorexia, nausea, vomiting, constipation, diarrhea, and hair loss) within

158 Chronic unexplained nausea and vomiting (CUNV) is a debilitating disease of unknown cau

159 severe hypercalcemia with failure to thrive, vomiting, dehydration, and nephrocalcinosis.

160 ially preventable conditions such as nausea, vomiting, dehydration, and pain.

161 noses were infectious causes (46.3%), nausea/vomiting/dehydration (26.8%), and pain (6.1%).

162 who presented with acute epigastric pain and vomiting, diagnosed to have an incarcerated diaphragmati

163 eloped abruptly with fevers, abdominal pain, vomiting, diarrhea, dehydration, and hemorrhage.

164 minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and blee

165 IGBs from the patient's body causes nausea, vomiting, discomfort, and even gastric mucous damage.

166 outh, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of

167 e associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infecti

168 revention of chemotherapy-induced nausea and vomiting during the 5-day (0-120 h) at-risk period after

169 revention of chemotherapy-induced nausea and vomiting during the at-risk period (120 h) after adminis

170 topenia, gastrointestinal events (diarrhoea, vomiting, dysgeusia, mucositis), fatigue, and hyponatrae

171 patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%).

172 5% CI, 2.8-8.5; specificity, 97%), 2 or more vomiting episodes (LR, 3.6; 95% CI, 3.1-4.1; specificity

173 rrent or prior optic neuritis or intractable vomiting episodes more frequently, had shorter time to m

174 =2 vomiting episodes without diarrhea or 1-2 vomiting episodes plus 1-2 loose/liquid stools within 24

175 anded case definition of AGE (by adding >/=2 vomiting episodes without diarrhea or 1-2 vomiting episo

176 the Canadian CT Head Rule (>/=65 years; >/=2 vomiting episodes, amnesia >30 minutes, pedestrian struc

177 f skull fracture, GCS score of 13, 2 or more vomiting episodes, decrease in GCS score, and pedestrian

178 ry recall of postingestive aversive effects (vomiting), evoked by repeatedly touching the food with c

179 than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal res

180 He did not have a history of nausea or vomiting, fever, weight loss, headache, photophobia, sei

181 fied acetylcysteine regimen resulted in less vomiting, fewer anaphylactoid reactions, and reduced nee

182 2%] vs four [4%] postoperatively), nausea or vomiting (four [3%] vs six [4%] preoperatively; four [4%

183 were pulmonary embolism (four patients; 8%), vomiting (four; 8%), dehydration (three; 6%), and diarrh

184 rated gastric emptying (P < .03) and reduced vomiting frequency (by approximately 60%) and severity v

185 ite score of these 4 subjective symptoms and vomiting frequency and severity.

186 daily e-diaries, in which patients recorded vomiting frequency and symptom scores (nausea, abdominal

187 nts given relamorelin had a 75% reduction in vomiting frequency compared with baseline, but this diff

188 Hospitalization rates and diarrhea and vomiting frequency were not significantly different betw

189 Endpoints were change from baseline in vomiting frequency, composite DG Symptom Severity score,

190 reduction in gastroenteritis, diarrhea, and vomiting GP in-hours consultations in children aged 0-4

191 vs grade 3, n=23 [2%] in the placebo group), vomiting (grade 3, n=47 [3%] vs n=5 [<1%]), and nausea (

192 neratinib vs 23 [2%] grade 3 with placebo), vomiting (grade 3: 47 [3%] vs five [<1%]), and nausea (g

193 puncture for chemotherapy-induced nausea and vomiting had low ROB.

194 l intake of ferrous iron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and cons

195 .89; 95% confidence interval [CI], .82-.97), vomiting (HR, 0.86; 95% CI, .75-.98), and fever (HR, 0.9

196 linking food exposure to typical symptoms of vomiting, hypotension, and diarrhea has lagged far behin

197 (eight grade 1 and five grade 2), nausea or vomiting in 15 patients (38%) (ten grade 1 and five grad

198 rse events were gastrointestinal (nausea and vomiting in four participants during pregnancy and three

199 e outbreaks that causes diarrhoea, fever and vomiting in humans.

200 s) are leading causes of severe diarrhea and vomiting in infants and young children.

201 revention of chemotherapy-induced nausea and vomiting in paediatric patients being treated with moder

202 e prevention of acute and delayed nausea and vomiting in patients receiving chemotherapy.

203 olanzapine for the prevention of nausea and vomiting in patients receiving highly emetogenic chemoth

204 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of

205 revention of chemotherapy-induced nausea and vomiting in patients with cancer after administration of

206 d to prevent chemotherapy-induced nausea and vomiting in patients with cancer.

207 n and a 30% reduction in odds of posttussive vomiting in persons aged 19 months-64 years.

208 findings suggest an effective treatment for vomiting in positive FPIES OFCs and allow for more confi

209 dence on effective treatments for nausea and vomiting in pregnancy and hyperemesis gravidarum.

210 y end points were control of both nausea and vomiting in the acute posttreatment period (first 24 hou

211 Inclusion of vomiting in the case definition resulted in a 20% improv

212 , respectively), and incidence of nausea and vomiting in the PACU (4 of 19 [21.1%] and 6 of 24 [25%],

213 and 6 of 23 [26.1%] for incidence of nausea/vomiting in the PACU).

214 or less, parent-reported moderate or severe vomiting in the previous 24 h, parent-reported severe fe

215 rrhea (in 51%), abdominal pain (in 40%), and vomiting (in 34%).

216 participants), abdominal pain (in six), and vomiting (in five).

217 luded cough (in 19 [56%] of 34 patients) and vomiting (in ten [29%]).

218 Chemotherapy-induced nausea and vomiting is a common side-effect of many antineoplastic

219 gain resulting from compensatory behaviors (vomiting, laxative use, fasting, overexercise) was signi

220 he multivariate logistic model, a history of vomiting, lower platelet count, elevated aspartate amino

221 12), weight loss (LR, 4.7; 95% CI, 2.1-7.2), vomiting (LR, 4.6; 95% CI, 2.5-8.0), and swollen lymph n

222 ing, urinary retention, increased nausea and vomiting, may delay same day discharge.

223 erature, age, recession, wheeze, asthma, and vomiting (mnemonic STARWAVe; AUROC 0.81, 0.76-0.85) dist

224 Severe AEs included vomiting (n = 32), dizziness (n = 16), headache (n = 11)

225 were anaemia (n=14), weight loss (n=12), and vomiting (n=10).

226 ), cough (n=32), nasopharyngitis (n=25), and vomiting (n=25).

227 Vomiting, nausea, and headache were the only treatment-e

228 Vomiting, nausea, asthenia/fatigue, and anorexia were co

229 ntly more stomatitis, myalgia or arthralgia, vomiting, nausea, fatigue, and peripheral neuropathy, wh

230 (ie, complete protection, total control, no vomiting, no nausea, score of Functional Living Index-Em

231 ho achieved complete response (defined as no vomiting, no retching, and no use of rescue medication)

232 ns: postembolization fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic

233 Nausea or vomiting occurred more frequently in the sertraline vs p

234 henia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the m

235 Hyperemesis gravidarum or severe nausea and vomiting of pregnancy affects women's physical, social a

236 east moderate symptoms of chronic nausea and vomiting of presumed gastric origin for a minimum of 6 m

237 Vomiting of the study medication occurred significantly

238 The primary end point was vomiting on POD 2.

239 oup (one had right loin pain, diarrhoea, and vomiting; one had malaise, headache, and chest pain; and

240 There was no history of vomiting or altered bowel habits.

241 an 18 years, with at least three episodes of vomiting or diarrhoea in the preceding 24 h and fewer th

242 ion to hospital (32 were pneumonia, two were vomiting or feeding disorders, one was septicaemia, and

243 ), intense fatigue or weakness (n=495, 68%), vomiting or nausea (n=365, 50%), and diarrhoea (n=294, 4

244 to withhold opioids when ADEs (i.e., nausea/vomiting or oversedation) were present together with hig

245 point was rate of complete response (ie, no vomiting or rescue treatment) from days 2 to 5 after che

246 abdominal discomfort for two months; nausea, vomiting or weight loss were not reported.

247 toms (OR 3.4 (1.8-6.7) vs mild symptoms) and vomiting (OR 3.1 (1.5-6.3).

248 rpse, body fluids, or a case with diarrhoea, vomiting, or bleeding).

249 tool specimens in children with diarrhoea or vomiting, or both.

250 in eating disorder symptoms such as binging, vomiting, or laxative abuse were observed between the se

251 between treatment arms with postdose nausea, vomiting, or other adverse events.

252 ia (P = .0012), GERD (P = .0001), and nausea/vomiting (P < .0001).

253 hea, fever, myalgias/arthralgias, nausea, or vomiting (P < .05) at admission.

254 king were presence of abdominal bloating and vomiting (p < 0.05).

255 y to have myalgias/arthralgias (P< .001) and vomiting (P = .02).

256 al functioning (P </= .001), less nausea and vomiting (P = .029 and .031, respectively) and less pain

257 ted less pain (p=0.0008) and less nausea and vomiting (p=0.02) and constipation (p=0.02).

258 eral nervous system, such as chronic nausea, vomiting, pain, and hypertension.

259 ale and seven subscales (fatigue, nausea and vomiting, pain, physical functioning, role functioning,

260 engue Identifier [ESDI]) included history of vomiting, platelet count, AST level.

261 ehydration (eight each [4%]), and diarrhoea, vomiting, pneumonia, and decreased appetite (four each [

262 Postoperative nausea and vomiting (PONV) continues to be one of the most common p

263 hyroidectomy reduce postoperative nausea and vomiting (PONV) in a randomized controlled trial?

264 ncluding migraines, postoperative nausea and vomiting (PONV), vertigo and morning sickness and observ

265 se for treatment of postoperative nausea and vomiting (PONV).

266 sia use, multimodal postoperative nausea and vomiting prophylaxis, multimodal sedation-hypnosis, and

267 Among patients with baseline vomiting, relamorelin had prokinetic effects and signifi

268 dications, notably HIV/AIDS cachexia, nausea/vomiting related to chemotherapy, neuropathic pain, and

269 er of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95

270 The primary outcome was absence of vomiting, retching, or need for rescue antiemetic treatm

271 Vomiting, retching, or need for rescue antiemetic treatm

272 py with high chemotherapy-induced nausea and vomiting risk (32.4% [n = 106795]).

273 health problems, such as acute gastritis and vomiting, road accident, high fever, or cardiovascular d

274 o, risk difference 3.7%, 95% CI 1.8-6.1) and vomiting (RR 2.43, 95% CI 1.83-3.23; p<0.0001; 8.0% osel

275 cores over the 14-day study period, trend in vomiting scores was better in the ondansetron group (P =

276 patient questionnaires showed a reduction in vomiting (severity), diarrhea (both incidence and severi

277 history of lower abdominal pain, nausea and vomiting since 2 days which was gradual in onset and pro

278 VD case included hiccups, anorexia, fatigue, vomiting, sore throat, and difficulty swallowing.

279 hospital stay, readmission rate, nausea and vomiting symptoms, decrease in quality of life, psycholo

280 Children with cyclic vomiting syndrome (CVS) have a high degree of maternal i

281 p), nausea (15 [4%] vs 17 [4%] patients) and vomiting (ten [2%] patients in each group); and nervous

282 (four [11%]), hypertension (four [11%]), and vomiting (three [8%]).

283 In the 119 patients (58.3%) with baseline vomiting, twice-daily relamorelin significantly reduced

284 cal neurologic deficits, chest pain, nausea, vomiting, unintentional weight loss, or recent trauma.

285 usion, conjunctivitis, hiccups, diarrhea, or vomiting was associated with increased likelihood of con

286 An important improvement of vomiting was observed in all three treatment groups.

287 The occurrence of vomiting was significantly higher in rotavirus diarrhea

288 Vomiting was the most commonly reported mild adverse eve

289 based on the percentage of cases who stopped vomiting, was compared in cases who received parenteral

290 Women reporting nausea/vomiting were less likely to be adherent in both the tam

291 Diarrhoea and nausea or vomiting were more common in the metformin group than in

292 Burping and nausea or vomiting were most severe in patients with cachexia (p <

293 nt), and headache, dizziness, diarrhoea, and vomiting were the most frequent adverse events in patien

294 testinal side effects (nausea, loose stools, vomiting) were common but did not limit therapy.

295 , retinal vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).

296 nic trioxide because of grade 3 diarrhea and vomiting with concurrent grade 3 hypokalemia and hyponat

297 spp, fever and vomiting with rotavirus, and vomiting with norovirus GII.

298 ampylobacter spp and Shigella spp, fever and vomiting with rotavirus, and vomiting with norovirus GII

299 Vomiting without diarrhea occurred among norovirus cases

300 Safety outcomes were the prevalence of vomiting, witnessed aspiration, and ICU-acquired pneumon